Isorinic acidCAS# 145757-60-4 |
2D Structure
Quality Control & MSDS
Package In Stock
Number of papers citing our products
Cas No. | 145757-60-4 | SDF | Download SDF |
PubChem ID | N/A | Appearance | Powder |
Formula | C18H16O7 | M.Wt | 344.3 |
Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Isorinic acid Dilution Calculator
Isorinic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9044 mL | 14.5222 mL | 29.0444 mL | 58.0889 mL | 72.6111 mL |
5 mM | 0.5809 mL | 2.9044 mL | 5.8089 mL | 11.6178 mL | 14.5222 mL |
10 mM | 0.2904 mL | 1.4522 mL | 2.9044 mL | 5.8089 mL | 7.2611 mL |
50 mM | 0.0581 mL | 0.2904 mL | 0.5809 mL | 1.1618 mL | 1.4522 mL |
100 mM | 0.029 mL | 0.1452 mL | 0.2904 mL | 0.5809 mL | 0.7261 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Justicidin D
Catalog No.:BCX0154
CAS No.:27041-98-1
- Chinensinaphthol methyl ether
Catalog No.:BCX0153
CAS No.:53965-11-0
- Justicidin B
Catalog No.:BCX0152
CAS No.:17951-19-8
- threo-7,9,9'-Trihydroxy-3,3'-dimethoxy-8-O-4'-neolignan 4-O-beta-D-glucopyranoside
Catalog No.:BCX0151
CAS No.:1009838-88-3
- Dehydropipernonaline
Catalog No.:BCX0150
CAS No.:107584-38-3
- Pyrolaside B analogue
Catalog No.:BCX0149
CAS No.:1053610-99-3
- 2,4,12-Octadecatrienoic acid isobutylamide
Catalog No.:BCX0148
CAS No.:151391-69-4
- Jatairidoid A
Catalog No.:BCX0147
CAS No.:1393577-29-1
- 3-Hydroxy-4',5,7-trimethoxyflavan
Catalog No.:BCX0146
CAS No.:3143-21-3
- 7-(Hydroxymethyl)-2-methyl-1,4-naphthalenedione
Catalog No.:BCX0145
CAS No.:145626-36-4
- Methyl piperate
Catalog No.:BCX0144
CAS No.:6190-46-1
- Periclymenosidic acid
Catalog No.:BCX0143
CAS No.:96681-56-0
- Melliferone
Catalog No.:BCX0156
CAS No.:377724-68-0
- Huzhangoside C
Catalog No.:BCX0157
CAS No.:96315-52-5
- Procumbenoside E
Catalog No.:BCX0158
CAS No.:220182-12-7
- Kaempferol 3-(2''-galloylglucoside)
Catalog No.:BCX0159
CAS No.:76343-90-3
- Lapathoside A
Catalog No.:BCX0160
CAS No.:373646-49-2
- Justicidin C
Catalog No.:BCX0161
CAS No.:17803-12-2
- Massonianoside A
Catalog No.:BCX0162
CAS No.:623945-11-9
- Justicidinoside C
Catalog No.:BCX0163
CAS No.:177912-23-1
- Retrofractamide C
Catalog No.:BCX0164
CAS No.:96386-33-3
- Gerardianin D
Catalog No.:BCX0165
CAS No.:2036276-69-2
- Pyrolone B
Catalog No.:BCX0166
CAS No.:1014978-30-3
- 3alpha-Acetyloxy-25-hydroxyolean-12-en-28-oic acid
Catalog No.:BCX0167
CAS No.:469895-08-7
Potential antithrombotic effect of two new phenylpropanoid sucrose esters and other secondary metabolites of Canna indica L. rhizome.[Pubmed:37749889]
Nat Prod Res. 2023 Sep 25:1-9.
Canna indica L. has been traditionally used to treat various diseases. Based on previously reported antithrombotic effect for this plant, two new phenylpropanoid sucrose esters (canindicoside A (1) and canindicoside B (2)) and seven known compounds: nepetoidin B (3), caffeic acid (4), ferulic acid (5), (R)-(+)-rosmarinic acid (6), Isorinic acid (7), (S)-(-)-rosmarinic acid (8) and (S)-(-)-rosmarinic acid methyl ester (9) were isolated from the ethyl acetate extract. Compounds were elucidated by NMR and MS spectroscopic methods. The antiplatelet effect was evaluated using turbidimetric method. Anticoagulant activity was examined by measuring activated partial thromboplastine time (APTT), prothrombin time, and thrombine time (TT). It was shown for the first time that both new phenylpropanoid sucrose esters 1 and 2, 7 and 9 displayed dose-dependent antiplatelet effects. 2 and 9 had the highest inhibitory activity on both adenosine diphosphate (ADP)- and collagen-induced platelet aggregation. Moreover, 1, 7 and 9 also exhibited anticoagulant activity. At 0.4 mg/mL, both 1 and 7 prolonged APTT compared to the negative control (p < 0.05), suggesting the possible inhibitory impact on the intrinsic coagulation pathway. Moreover, 9 at 0.4 mg/mL exerted higher TT values than the negative control (p < 0.05). C. indica and its bioactive phytochemicals are potential candidates for development of anti-thrombosis therapy.
Construction of a chimeric biosynthetic pathway for the de novo biosynthesis of rosmarinic acid in Escherichia coli.[Pubmed:25205019]
Chembiochem. 2014 Nov 3;15(16):2393-401.
Hydroxycinnamic acid esters (HCEs) are widely-distributed phenylpropanoid-derived plant natural products. Rosmarinic acid (RA), the most well-known HCE, shows promise as a treatment for cancer and neurological disorders. In contrast to extraction from plant material or plant cell culture, microbial production of HCEs could be a sustainable, controlled means of production. Through the overexpression of a six-enzyme chimeric bacterial and plant pathway, we show the de novo biosynthesis of RA, and the related HCE Isorinic acid (IA), in Escherichia coli. Probing the pathway through precursor supplementation showed several potential pathway bottlenecks. We demonstrated HCE biosynthesis using three plant rosmarinic acid synthase (RAS) orthologues, which exhibited different levels of HCE biosynthesis but produced the same ratio of IA to RA. This work serves as a proof-of-concept for a microbial production platform for HCEs by using a modular biosynthetic approach to access diverse natural and non-natural HCEs.
Phenolic constituents from Perovskia atriplicifolia.[Pubmed:16644529]
Nat Prod Res. 2006 Apr;20(4):347-53.
Perovskoate, an Isorinic acid derivative (1) and perovskoside, the catechol derivative (2) have been isolated from the ethyl acetate soluble fraction of the whole plant of Perovskia atriplicifolia and assigned the structure 3(7-hydroxyphenyl)-2-hydroxy propanoic acid; (R)-form, 2-O-(6',7'-dihydroxy-E-cinnamoyl) (1) and 2-methoxy-4-(undecyl-4'-O-beta-D-glucopyranosyl) phenol (2). In addition, caffeic acid (3) and ferulic acid (4) have been reported for the first time from this species. The structures of these compounds were assigned on the basis of 1D and 2D NMR techniques. The compound 1 showed significant inhibitory activity against lipoxygenase and weak to moderate activity against cholinesterases.